Introduction:
Sterling Pharma Solutions invests $8 Million into a new facility at its UK to strengthen and expand its milling, micronisation and solid form capabilities.
Features:
The contract development and manufacturing organization will meet growing demand for pharmaceutical API particle size control technology.
It will meet Sterling’s laboratory capabilities to provide a full solid form offering including polymorph screening, salt selection and particle engineering and crystallization scale-up.
Four new milling areas will contain a range of new technologies, including mechanical milling, spiral jet milling and small lab scale trial mills.
The facility will also provide containment to handle OEB 4 classified molecules and offer ISO 8 cleanroom environments by supporting the CDMO’s expertise in handling potent and hazardous materials.
This latest investment helps Sterling to cater for growing market demands including the necessity for high potency capabilities to reflect the global drug pipeline.
The new facility will strengthen current offerings of Sterling by adding additional milling, micronisation and solid form capabilities.
It is expected to be operation by mid 2018. The milling, micronisation and solid form facility will create more than 15 jobs over the next 18 months, bringing Sterling’s total workforce to around 400 employees.
By expanding these capabilities, Sterling plans to ensure the diverse needs of customers globally.
Specifications:
| Name | Sterling Pharma Solutions |
| Location | United Kingdom (UK) |
| Type | Expansion |
| Parties Involved | Sterling Pharma Solutions |
| Budget | $8 Million |
